

IN THE CLAIMS:

Please amend claim 40 to read as follows. All claims pending, including those unchanged by the present amendment, are reproduced below for the convenience of the Examiner.

1 1.-31. (Canceled)

1 32. (Original) A composition comprising:
2 an effective amount of a biologically active agent;
3 a delivery-enhancing transporter having sufficient guanidino or amidino moieties to
4 increase delivery of the biologically active agent across a biological barrier
5 compared to the delivery of the biologically active agent in the absence of the
6 transporter; and
7 a pharmaceutically acceptable carrier.

1 33. (Original) The composition of claim 32, wherein the biologically active
2 agent is selected from the group consisting of antiviral agents, antibacterial agents, antifungal
3 agents, antiproliferative agents, immunosuppressive agents, vitamins, analgesic agents and
4 hormones.

1 34. (Original) The composition of claim 33, wherein the biologically active
2 agent is an antiviral agent selected from the group consisting of acyclovir, famciclovir,
3 ganciclovir, foscarnet, idoxuridine, sorivudine, trifluridine, valacyclovir, cidofovir, didanosine,
4 stavudine, zalcitabine, zidovudine, ribavirin and rimantadine.

1 35. (Original) The composition of claim 32, wherein the biologically active
2 agent is an antibacterial agent selected from the group consisting of nafcillin, oxacillin,

3 penicillin, amoxicillin, ampicillin, cefotaxime, ceftriaxone, rifampin, minocycline, ciprofloxacin,
4 norfloxacin, erythromycin and vancomycin.

1 36. (Original) The composition of claim 32, wherein the biologically active
2 agent is an antifungal agent selected from the group consisting of amphotericin, itraconazole,
3 ketoconazole, miconazole, nystatin, clotrimazole, fluconazole, ciclopirox, econazole, naftifine,
4 terbinafine and griseofulvin.

1 37. (Original) The composition of claim 32, wherein the biologically active
2 agent is an antineoplastic agent selected from the group consisting of pentostatin, 6-
3 mercaptopurine, 6-thioguanine, methotrexate, bleomycins, etoposide, teniposide, dactinomycin,
4 daunorubicin, doxorubicin, mitoxantrone, hydroxyurea, 5-fluorouracil, cytarabine, fludarabine,
5 mitomycin, cisplatin, procarbazine, dacarbazine, paclitaxel, colchicine, and the vinca alkaloids.

1 38. (Previously presented) The composition of claim 32, wherein the
2 biologically active agent is an immunosuppressive agent selected from the group consisting of
3 methotrexate, azathioprine, fluorouracil, hydroxyurea, 6-thioguanine, cyclophosphamide,
4 mechloroethamine hydrochloride, carmustine, cyclosporine, taxol or a phosphate-cleavable taxol
5 conjugate, tacrolimus, vinblastine, dapsone and sulfasalazine.

1 39. (Original) The composition of claim 32, wherein the biologically active
2 agent is an analgesic agent selected from the group consisting of lidocaine, bupivacaine,
3 novocaine, procaine, tetracaine, benzocaine, cocaine, mepivacaine, etidocaine, proparacaine
4 ropivacaine and prilocaine.

1 40. (Currently Amended) The composition of claim ~~33~~ 32, wherein the delivery
2 enhancing transporter is a peptide having from about 6 to about 15 amino acids residues wherein
3 from 6 to about 12 residues are selected from the group consisting of L-arginine, D-arginine, L-
4 homoarginine and D-homoarginine.
